TY - JOUR
T1 - AACAP 2002 research forum
T2 - Placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology
AU - March, John
AU - Kratochvil, Christopher
AU - Clarke, Gregory
AU - Beardslee, William
AU - Derivan, Albert
AU - Emslie, Graham
AU - Green, Evelyn P.
AU - Heiligenstein, John
AU - Hinshaw, Stephen
AU - Hoagwood, Kimberly
AU - Jensen, Peter
AU - Lavori, Philip
AU - Leonard, Henrietta
AU - McNulty, James
AU - Michaels, M. Alex
AU - Mossholder, Andrew
AU - Osher, Trina
AU - Petti, Theodore
AU - Prentice, Ernest
AU - Vitiello, Benedetto
AU - Wells, Karen
N1 - Funding Information:
The 2002 Research Forum was supported by American Academy of Child and Adolescent Psychiatry Workgroup on Research.
PY - 2004/8
Y1 - 2004/8
N2 - Objective: The use of placebo in the pediatric age group has come under increasing scrutiny. At the 2002 Annual Meeting of the American Academy of Child and Adolescent Psychiatry, the Academy's Workgroup on Research conducted a research forum. The purpose was to identify challenges and their solutions regarding the use of placebo in randomized controlled trials in pediatric psychopharmacology. Method: Workgroups focused on problems and solutions in five areas: ethics and human subjects, research design and statistics, partnering with consumers, U.S. Food and Drug Administration and pharmaceutical industry perspectives, and psychosocial treatments. Results: In many but not all circumstances, inclusion of a placebo control is essential to meet the scientific goals of treatment outcome research. Innovative research designs; involvement of consumers in planning and implementing research; flexibility by industry, academia, the National Institutes of Health, and regulatory agencies acting in partnership; and concomitant use of evidence-based psychosocial services can and should assist in making placebo-controlled trials acceptable. Conclusions: Properly designed placebo-controlled trials remain necessary, ethical, and feasible.
AB - Objective: The use of placebo in the pediatric age group has come under increasing scrutiny. At the 2002 Annual Meeting of the American Academy of Child and Adolescent Psychiatry, the Academy's Workgroup on Research conducted a research forum. The purpose was to identify challenges and their solutions regarding the use of placebo in randomized controlled trials in pediatric psychopharmacology. Method: Workgroups focused on problems and solutions in five areas: ethics and human subjects, research design and statistics, partnering with consumers, U.S. Food and Drug Administration and pharmaceutical industry perspectives, and psychosocial treatments. Results: In many but not all circumstances, inclusion of a placebo control is essential to meet the scientific goals of treatment outcome research. Innovative research designs; involvement of consumers in planning and implementing research; flexibility by industry, academia, the National Institutes of Health, and regulatory agencies acting in partnership; and concomitant use of evidence-based psychosocial services can and should assist in making placebo-controlled trials acceptable. Conclusions: Properly designed placebo-controlled trials remain necessary, ethical, and feasible.
KW - Adolescence
KW - Placebo
KW - Psychopharmacology
KW - Randomized controlled trial
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=3242796813&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3242796813&partnerID=8YFLogxK
U2 - 10.1097/01.chi.0000129606.83206.77
DO - 10.1097/01.chi.0000129606.83206.77
M3 - Article
C2 - 15266201
AN - SCOPUS:3242796813
SN - 0890-8567
VL - 43
SP - 1046
EP - 1056
JO - Journal of the American Academy of Child and Adolescent Psychiatry
JF - Journal of the American Academy of Child and Adolescent Psychiatry
IS - 8
ER -